- Home
- NMP vs ENTA Comparison
NMP vs ENTA Comparison
Compare NMP & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMP
- ENTA
- Stock Information
- Founded
- NMP 2024
- ENTA 1995
- Country
- NMP United States
- ENTA United States
- Employees
- NMP N/A
- ENTA N/A
- Industry
- NMP Blank Checks
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- NMP Finance
- ENTA Health Care
- Exchange
- NMP Nasdaq
- ENTA Nasdaq
- Market Cap
- NMP 158.8M
- ENTA 164.6M
- IPO Year
- NMP 2025
- ENTA 2013
- Fundamental
- Price
- NMP $10.00
- ENTA $10.54
- Analyst Decision
- NMP
- ENTA Strong Buy
- Analyst Count
- NMP 0
- ENTA 5
- Target Price
- NMP N/A
- ENTA $21.00
- AVG Volume (30 Days)
- NMP 42.9K
- ENTA 1.6M
- Earning Date
- NMP 01-01-0001
- ENTA 11-24-2025
- Dividend Yield
- NMP N/A
- ENTA N/A
- EPS Growth
- NMP N/A
- ENTA N/A
- EPS
- NMP N/A
- ENTA N/A
- Revenue
- NMP N/A
- ENTA $64,806,000.00
- Revenue This Year
- NMP N/A
- ENTA $0.07
- Revenue Next Year
- NMP N/A
- ENTA N/A
- P/E Ratio
- NMP N/A
- ENTA N/A
- Revenue Growth
- NMP N/A
- ENTA N/A
- 52 Week Low
- NMP $9.90
- ENTA $4.09
- 52 Week High
- NMP $10.00
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- NMP N/A
- ENTA 51.46
- Support Level
- NMP N/A
- ENTA $10.20
- Resistance Level
- NMP N/A
- ENTA $11.59
- Average True Range (ATR)
- NMP 0.00
- ENTA 0.63
- MACD
- NMP 0.00
- ENTA -0.18
- Stochastic Oscillator
- NMP 0.00
- ENTA 20.29
About NMP NMP Acquisition Corp. Class A Ordinary Shares
NMP Acquisition Corp is a blank check company.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.